Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJul 30, 2026
DataAggregated Company Financials
Companies7
  • 7D5.7%
  • 3M17.7%
  • 1Y0.2%
  • YTD11.1%

Over the last 7 days, the Life Sciences industry has dropped 1.1%, driven by Bachem Holding declining 5.7%. As for the longer term, the industry's performance has been flat for the past year. Earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 30 Jul 2026CHF 54.2bCHF 10.5bCHF 1.3b37.1x43x5.2x
Sat, 27 Jun 2026CHF 50.7bCHF 10.1bCHF 1.1b38.6x46.5x5x
Mon, 25 May 2026CHF 48.1bCHF 10.1bCHF 1.1b38.7x44.1x4.8x
Wed, 22 Apr 2026CHF 48.6bCHF 10.1bCHF 1.1b35x42.5x4.8x
Fri, 20 Mar 2026CHF 44.6bCHF 10.1bCHF 1.1b31.3x39x4.4x
Sun, 15 Feb 2026CHF 49.2bCHF 10.1bCHF 1.3b31.2x38.6x4.9x
Tue, 13 Jan 2026CHF 52.5bCHF 10.6bCHF 1.1b34x47.8x4.9x
Thu, 11 Dec 2025CHF 48.7bCHF 10.6bCHF 1.1b28x44.3x4.6x
Sat, 08 Nov 2025CHF 48.0bCHF 10.6bCHF 1.1b27.8x43.7x4.5x
Mon, 06 Oct 2025CHF 51.1bCHF 10.6bCHF 1.1b31.7x46.5x4.8x
Wed, 03 Sep 2025CHF 52.4bCHF 10.7bCHF 1.1b33x47.5x4.9x
Fri, 01 Aug 2025CHF 54.2bCHF 10.7bCHF 1.1b34.6x47.2x5.1x
Sun, 29 Jun 2025CHF 52.8bCHF 10.1bCHF 1.0b33.6x50.8x5.2x
Tue, 27 May 2025CHF 52.6bCHF 10.1bCHF 1.0b31.4x50.6x5.2x
Thu, 24 Apr 2025CHF 51.4bCHF 10.1bCHF 1.0b29.2x50.2x5.1x
Sat, 22 Mar 2025CHF 53.6bCHF 10.1bCHF 1.0b33.1x52.6x5.3x
Mon, 17 Feb 2025CHF 57.1bCHF 10.1bCHF 1.0b36.4x56.7x5.7x
Wed, 15 Jan 2025CHF 52.6bCHF 10.2bCHF 943.4m34.2x55.8x5.2x
Fri, 13 Dec 2024CHF 54.4bCHF 10.2bCHF 943.6m39.3x57.7x5.3x
Sun, 10 Nov 2024CHF 55.9bCHF 10.2bCHF 943.4m43.8x59.2x5.5x
Tue, 08 Oct 2024CHF 54.3bCHF 10.2bCHF 943.5m41.5x57.5x5.3x
Thu, 05 Sep 2024CHF 56.2bCHF 10.2bCHF 937.1m44x60x5.5x
Sat, 03 Aug 2024CHF 57.4bCHF 10.2bCHF 924.3m44.5x62.1x5.6x
Mon, 01 Jul 2024CHF 51.2bCHF 10.3bCHF 1.0b44x51.1x5x
Wed, 29 May 2024CHF 53.0bCHF 10.3bCHF 1.0b44x53x5.2x
Fri, 26 Apr 2024CHF 53.9bCHF 10.3bCHF 1.0b43.3x53.9x5.3x
Sun, 24 Mar 2024CHF 57.2bCHF 10.2bCHF 1.0b45.9x56.9x5.6x
Tue, 20 Feb 2024CHF 50.0bCHF 10.2bCHF 1.0b46.3x49x4.9x
Thu, 18 Jan 2024CHF 41.1bCHF 9.8bCHF 1.5b30.9x27.5x4.2x
Sat, 16 Dec 2023CHF 41.2bCHF 9.8bCHF 1.5b32.6x27.6x4.2x
Mon, 13 Nov 2023CHF 39.6bCHF 9.8bCHF 1.5b27.5x26.5x4x
Wed, 11 Oct 2023CHF 47.1bCHF 9.8bCHF 1.5b32.2x31.5x4.8x
Fri, 08 Sep 2023CHF 52.7bCHF 9.8bCHF 1.5b36.3x35.4x5.4x
Sun, 06 Aug 2023CHF 52.9bCHF 9.8bCHF 1.5b35.3x34.2x5.4x
Price to Earnings Ratio

34.2x


Total Market Cap: CHF 52.9bTotal Earnings: CHF 1.5bTotal Revenue: CHF 9.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 41.9x which is lower than its 3-year average PE of 46.9x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 6.5% per year over the last three years.
  • Meanwhile revenues for these companies have grown 2.3% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.03%
Healthcare5.70%
Life Sciences5.72%
Clinical Research and Equipment5.72%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 574.807.2%
+CHF 2.7b		0.1%PE37.1x
SFZN Siegfried HoldingCHF 76.956.8%
+CHF 214.7m		-18.2%PE20x
TECN Tecan GroupCHF 185.503.7%
+CHF 82.7m		13.5%PS2.6x
SKAN SKAN GroupCHF 59.805.8%
+CHF 74.2m		-21.5%PE82.6x
PPGN PolyPeptide GroupCHF 43.850.2%
+CHF 3.3m		92.3%PS4x

Latest News

LONN
CHF 574.80
Lonza Group
7D
7.2%
1Y
0.1%
Narrative Update • Jul 24

LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside

Lonza Group's updated analyst price target edges higher to CHF 678, supported by broader target increases across the Street toward CHF 640 to CHF 760 as analysts factor in revised assumptions on fair value, discount rate, revenue growth, profit margin and future P/E levels. Analyst Commentary Recent research on Lonza Group points to a mixed but generally constructive stance, with several price target adjustments clustering between CHF 590 and CHF 760.
SFZN
CHF 76.95
Siegfried Holding
7D
6.8%
1Y
-18.2%
BANB
CHF 73.60
Bachem Holding
7D
-2.1%
1Y
5.0%
TECN
CHF 185.50
Tecan Group
7D
3.7%
1Y
13.5%
Narrative Update • Jul 20

TECN: Margin Execution And India Expansion Will Shape Fairly Valued Outlook

The analyst price target for Tecan Group has been raised by CHF 8.50 to CHF 175.48, with analysts pointing to updated fair value assumptions, a slightly lower discount rate, and an ongoing focus on margin potential as reflected in recent CHF 142 to CHF 208 Street targets. Analyst Commentary Street research on Tecan Group has become more active, with several firms updating price targets and ratings.
PPGN
CHF 43.85
PolyPeptide Group
7D
0.2%
1Y
92.3%
SKAN
CHF 59.80
SKAN Group
7D
5.8%
1Y
-21.5%
Narrative Update • Jun 17

SKAN: Dividend Payouts And Order Backlog Will Support Future Returns

Analysts have kept their SKAN Group price target steady at CHF 62.50, noting that small adjustments to the discount rate and future P/E assumptions did not materially change their overall valuation view. What’s in the News for SKAN Group The Board of Directors of SKAN Group AG plans to propose a dividend of CHF 0.22 per share to the Annual General Meeting on May 7, 2026, corresponding to a 30% payout ratio.
XLS
CHF 16.70
Xlife Sciences
7D
-0.6%
1Y
-28.6%